PF-07220060 Tablet Forms in Healthy Adults

Phase 1

Recruiting

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours pf-07220060 post-dose

Awards & highlights

Summary

This trial compares two formulations of a medicine (PF-07220060) and how they are absorbed into the bloodstream. It also looks at the effects of food & Rabeprazole medicine on the uptake of the medicine.

Who is the study for?

Healthy adults aged 18-65 with a BMI of 17.5-30.5 kg/m2 and weight over 50 kg can join this study. They must be in good health as confirmed by medical exams, tests, and have no history of conditions affecting drug absorption or serious diseases like HIV or hepatitis.Check my eligibility

What is being tested?

The trial is testing two different tablet forms of PF-07220060 to see how they are absorbed into the bloodstream, with and without food, and under the influence of Rabeprazole (a proton pump inhibitor).See study design

What are the potential side effects?

Potential side effects aren't specified but may include reactions typical for clinical trials such as nausea, headache, digestive issues or allergic reactions depending on individual tolerance to PF-07220060.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours pf-07220060 post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours pf-07220060 post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours pf-07220060 post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations

Maximum Observed Plasma Concentration (Cmax) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations

Secondary outcome measures

AUCinf of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations at a second dose level

AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fasted condition

AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fed condition

+11 more